A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Schizophrenia

Treatments: Drug: Paliperidone Palmitate 3-Month Formulation (PP3M)

Study type: Observational

Funder types: Industry

Identifiers

NCT03809325

R092670SCH4066 (Other Identifier)

CR108568

Details and patient eligibility

About

The purpose of this study is to explore the experience with paliperidone palmitate 3-month formulation (PP3M) treatment of participants and their corresponding physicians, nurses and carers, to understand the impact of less frequent injections from their perspective.

Enrollment: 225 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a diagnosis of schizophrenia (according to International Classification of Diseases [ICD]-10)
• Be currently receiving PP3M and have previously received 4 to 6 injections of PP3M
• Have the required language skills to participate in the online questionnaire, in the opinion of the physician
• Be able and willing to provide their informed consent for study participation

Exclusion criteria

• Has received involuntary treatment with PP3M
• Was switched to PP3M treatment within a clinical trial

Trial design

225 participants in 1 patient group

Participants with Schizophrenia

Description:

No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.

Treatment:

Drug: Paliperidone Palmitate 3-Month Formulation (PP3M)